Matinas BioPharma terminates MAT2203 partnership, cuts 80% workforce, ceases development, considers dissolution

Matinas BioPharma Holdings, Inc.

Partnership negotiations for MAT2203 global rights terminated; prospective partner withdrew.
80% workforce reduction of 15 positions, including CMO, CBO, and CTO, effective Oct 31, 2024.
All product development ceased; exploring asset sale of MAT2203 or winddown/dissolution of the company.
CMO James Ferguson terminated; severance ~$500k (12 months base salary plus benefits).

item 2.05 item 2.06 item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

James Ferguson

Chief Medical Officer

MTNB · Matinas BioPharma Holdings, Inc.

Effective: 2024-10-31
Filed: October 31, 2024, 7:59 PM ET

the employment of James Ferguson, M.D., the Company’s Chief Medical Officer, was terminated effective October 31, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Ferguson was terminated as Chief Medical Officer at Matinas BioPharma Holdings, Inc..

Action: terminated
Role: Chief Medical Officer

Exact text from the filing

the employment of James Ferguson, M.D., the Company’s Chief Medical Officer, was terminated effective October 31, 2024.

View on SEC.gov

Matinas BioPharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-043130

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.